{"id":"NCT05149313","sponsor":"Almirall, S.A.","briefTitle":"A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine","officialTitle":"A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-12-23","primaryCompletion":"2023-01-30","completion":"2024-05-07","firstPosted":"2021-12-08","resultsPosted":"2024-11-06","lastUpdate":"2025-05-20"},"enrollment":331,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis, Atopic","Eczema"],"interventions":[{"type":"BIOLOGICAL","name":"Lebrikizumab","otherNames":[]},{"type":"DRUG","name":"Lebrikizumab-matching Placebo","otherNames":[]}],"arms":[{"label":"Lebrikizumab","type":"EXPERIMENTAL"},{"label":"Lebrikizumab-matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.","primaryOutcome":{"measure":"Double-blind Induction Period: Percentage of Participants Who Achieved Eczema Area and Severity Index (EASI) 75 (>=75% Reduction From Baseline in EASI Score) at Week 16","timeFrame":"At Week 16","effectByArm":[{"arm":"Double-blind Induction Period: Lebrikizumab +TCS","deltaMin":68.4,"sd":null},{"arm":"Double-blind Induction Period: Placebo +TCS","deltaMin":40.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":48,"countries":["Austria","Belgium","France","Germany","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":220},"commonTop":["Nasopharyngitis","Conjunctivitis","Conjunctivitis allergic","Upper respiratory tract infection","COVID-19"]}}